{"analyses":[{"ciLowerLimit":"0.84","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.01","groupDescription":"GCSF treatment decision (under vs correct) as predictor for ANC","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0683","paramType":"Slope","paramValue":"0.92","statisticalComment":"degrees of freedom: 3181","statisticalMethod":"Regression, Logistic","testedNonInferiority":false},{"ciLowerLimit":"0.82","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.96","groupDescription":"GCSF decision (Over vs correct) as predictor for ANC","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0019","paramType":"Slope","paramValue":"0.89","statisticalComment":"degrees of freedom: 3181","statisticalMethod":"Regression, Logistic","testedNonInferiority":false},{"ciLowerLimit":"0.94","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.15","groupDescription":"GCSF decision (Under vs over) as predictor for ANC","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.4469","paramType":"Slope","paramValue":"1.04","statisticalComment":"degrees of freedom: 3181","statisticalMethod":"Regression, Logistic","testedNonInferiority":false},{"ciLowerLimit":"1.03","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.19","groupDescription":"Study drug dose (higher vs lower) as predictor for ANC","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0079","paramType":"Slope","paramValue":"1.11","statisticalMethod":"Regression, Logistic","testedNonInferiority":false},{"ciLowerLimit":"0.72","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.91","groupDescription":"Tumor type (hematological vs solid) as predictor for ANC","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0004","paramType":"Slope","paramValue":"0.81","statisticalMethod":"Regression, Logistic","testedNonInferiority":false},{"ciLowerLimit":"0.80","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.92","groupDescription":"Patient gender (female vs male) as predictor for ANC","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Slope","paramValue":"0.86","statisticalMethod":"Regression, Logistic","testedNonInferiority":false},{"ciLowerLimit":"1.01","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.08","groupDescription":"ECOG (per 1 point) as predictor for ANC","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0235","paramType":"Slope","paramValue":"1.04","statisticalMethod":"Regression, Linear","testedNonInferiority":false},{"ciLowerLimit":"1.02","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.05","groupDescription":"Hb (per g/dL) as predictor for ANC","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Slope","paramValue":"1.03","statisticalMethod":"Regression, Linear","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1185"}]}]}],"denomUnitsSelected":"Participants","denoms":[{"counts":[{"groupId":"OG000","value":"1185"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"4333"}],"units":"cycles"}],"description":"Objective 6: To examine the multilevel determinants (patient, center) of hematological outcomes of primary and secondary prophylaxis with EP2006 to better understand the variability in outcomes achieved.\n\nHierarchical modeling was used to test the relationship of patient- and physician/center-level variables and treatment response in terms of ANC. This analysis was conducted at the cycle level using a 1-cycle lag between treatment patterns and outcomes, that is study drug treatment patterns in one cycle predicted the ANC value at the beginning of the next cycle. Log-transformed ANC values were used.\n\nTable presents predictors for ANC: GCSF decision, study drug dose, tumor type, patient gender, ECOG, Hb\n\nSince log-transformed Absolute Neutrophil Count (ANC) values were used, Exp(beta) can be interpreted in terms of % change in ANC for each unit change in predictor or for each category relative to the referent (for categorical variables); Hb=Hemoglobin","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG000","title":"EP2006"}],"paramType":"NUMBER","populationDescription":"Cycles for patients in evaluable sample with data","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"Predictors of Absolute Neutrophil Count","type":"PRIMARY","typeUnitsAnalyzed":"cycles","unitOfMeasure":"participants"}